2019
DOI: 10.1371/journal.pone.0217340
|View full text |Cite
|
Sign up to set email alerts
|

Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

Abstract: Purpose To compare the effectiveness of octreotide/everolimus vs . sunitinib for the systemic treatment of recurrent aggressive meningiomas. Methods 31 patients with recurrent or refractory WHO II or WHO III meningiomas were examined in two reference centers in Colombia. Patients who had systemic treatment (sunitinib, everolimus/octreotide) and a complete follow-up were included. Overall survival (OS), progression-free survival (PFS) and toxic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
61
0
1

Year Published

2021
2021
2025
2025

Publication Types

Select...
4
3

Relationship

1
6

Authors

Journals

citations
Cited by 24 publications
(62 citation statements)
references
References 20 publications
0
61
0
1
Order By: Relevance
“…The standard systemic therapies, such as sunitinib and everolimus/octreotide, have been evaluated to control aggressively recurrent meningiomas, but their clinical efficiency is poor [ 14 , 15 , 16 ]. More recently, the Lutathera combining [ 177 Lu]Lu-DOTA-TATE with [ 68 Ga]Ga-DOTA-TATE or [ 68 Ga]Ga-DOTA-TOC DOTA-(D-Phe1, Tyr3)-octreotide is being evaluated in clinical trials for meningioma treatment [ 11 , 44 , 45 ].…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…The standard systemic therapies, such as sunitinib and everolimus/octreotide, have been evaluated to control aggressively recurrent meningiomas, but their clinical efficiency is poor [ 14 , 15 , 16 ]. More recently, the Lutathera combining [ 177 Lu]Lu-DOTA-TATE with [ 68 Ga]Ga-DOTA-TATE or [ 68 Ga]Ga-DOTA-TOC DOTA-(D-Phe1, Tyr3)-octreotide is being evaluated in clinical trials for meningioma treatment [ 11 , 44 , 45 ].…”
Section: Resultsmentioning
confidence: 99%
“…The anti-SSTR2 ADC had no obvious off-target effects on body weight, overall survival, and major organs, which indicates that it is a safe targeted therapy for SSTR2-positive meningioma. The standard systemic therapies, such as sunitinib and everolimus/octreotide, have been evaluated to control aggressively recurrent meningiomas, but their clinical efficiency is poor [14][15][16]. More recently, the Lutathera combining [ 177 Lu]Lu-DOTA-TATE with [ 68 Ga]Ga-DOTA-TATE or [ 68 Ga]Ga-DOTA-TOC DOTA-(D-Phe1, Tyr3)-octreotide is being evaluated in clinical trials for meningioma treatment [11,44,45].…”
Section: Toxicity Evaluationmentioning
confidence: 99%
See 2 more Smart Citations
“…As an orally administered small tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), KIT and platelet-derived growth factor receptor, sunitinib has been demonstrated active in patients with recurrent malignant meningioma in a phase II trial where the 6month progression-free survival (PFS) rate in the cohort of anaplastic and atypical meningiomas was 42% and the expression of VEGFR2 in the tumor tissue was associated with favorable PFS (16). Moreover, sunitinib showed similar efficacy and safety in the systemic management of refractory meningiomas compared with octreotide/everolimus (17).…”
Section: Discussionmentioning
confidence: 99%